Open AccessMutant p53 protein in serum could be used as a molecular marker in human breast cancer
Author(s) -
Gabriela Andrea Balogh,
Daniel Mailo,
María Marta Corte,
P Roncoroni,
Héctor Nardi,
E. Chris Vincent,
Domingo Martínez,
M E Cafasso,
Alejandro Frizza,
Gorka Ruiz de Garibay Ponce,
Elena Barutta,
Pablo Lizarraga,
Guillermo Lizarraga,
Carlos Roberto Monti,
E Paolillo,
R.A. Vincent,
R Quatroquio,
C Grimi,
Horacio V. Maturi,
M Aimale,
C Spinsanti,
Héctor Pérez-Montero,
Javier De Santiago,
L.P. Shulman,
Marcos L. Rivadulla,
Mario R. Machiavelli,
Ghada M. Salum,
M. Cuevas,
J Picolini,
A Gentili,
Roberto Gentili,
José Mordoh
Publication year - 2006
Publication title -
international journal of oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.405
H-Index - 122
ISSN - 1019-6439
DOI - 10.3892/ijo.28.4.995
Subject(s) - immunohistochemistry , breast cancer , biology , oncogene , cancer research , cancer , tumor suppressor gene , molecular medicine , breast carcinoma , mutant , serology , ca 15 3 , antibody , breast disease , mutation , carcinogenesis , pathology , gene , ca15 3 , cell cycle , immunology , medicine , genetics
p53 wild-type is a tumor suppressor gene involved in DNA gene transcription or DNA repair mechanisms. When damage to DNA is unrepairable, p53 induces programmed cell death (apoptosis). The mutant p53 gene is the most frequent molecular alteration in human cancer, including breast cancer. Here, we analyzed the genetic alterations in p53 oncogene expression in 55 patients with breast cancer at different stages and in 8 normal women. We measured by ELISA assay the serum levels of p53 mutant protein and p53 antibodies. Immunohistochemistry and RT-PCR using specific p53 primers as well as mutation detection by DNA sequencing were also evaluated in breast tumor tissue. Serological p53 antibody analysis detected 0/8 (0%), 0/4 (0%) and 9/55 (16.36%) positive cases in normal women, in patients with benign breast disease and in breast carcinoma, respectively. We found positive p53 mutant in the sera of 0/8 (0.0%) normal women, 0/4 (0%) with benign breast disease and 29/55 (52.72%) with breast carcinoma. Immunohistochemistry evaluation was positive in 29/55 (52.73%) with mammary carcinoma and 0/4 (0%) with benign breast disease. A very good correlation between p53 mutant protein detected in serum and p53 accumulation by immunohistochemistry (83.3% positive in both assays) was found in this study. These data suggest that detection of mutated p53 could be a useful serological marker for diagnostic purposes.